OncoMatch/Clinical Trials/NCT04063527
Phase III Trial of Stage I Ovarian Cancer After Surgery
Is NCT04063527 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies adjuvant chemotherapy for epithelial ovarian cancer.
Treatment: adjuvant chemotherapy — To compare the Overall survival of adjuvant chemotherapy versus observation in stage I epithelial ovarian cancer after comprehensive staging surgery
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Disease stage
Required: Stage IA(GRADE2/3, CLEAR CELL CARCINOMA), IB(GRADE2/3, CLEAR CELL CARCINOMA), IC(B)(ALL DEGREE OF DIFFERENTIATION AND ALL HISTOLOGIC TYPE) (FIGO)
Excluded: Stage IC(A), IC(1), IC(2)
FIGO Stages Ia(Grade2/3, clear cell carcinoma), Ib(Grade2/3, clear cell carcinoma) and Ic(b)(all degree of differentiation and all histologic type)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04063527 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IA(GRADE2/3, CLEAR CELL CARCINOMA) or IB(GRADE2/3, CLEAR CELL CARCINOMA) or IC(B)(ALL DEGREE OF DIFFERENTIATION AND ALL HISTOLOGIC TYPE) is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages